Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ave1625
1. 358970-97-5
2. Ave-1625
3. Ave1625
4. Drinabant [inn]
5. Ave 1625
6. 61s98rll5i
7. N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-n-(3,5-difluorophenyl)methanesulfonamide
8. N-(1-(bis(4-chlorophenyl)methyl)azetidin-3-yl)-n-(3,5-difluorophenyl)methanesulfonamide
9. Unii-61s98rll5i
10. Drinabant [who-dd]
11. Schembl684143
12. Chembl3545166
13. Dtxsid50189455
14. Zinc59299699
15. Hy-14788
16. Cs-0003562
17. 970d975
18. Q5307675
19. Methanesulfonamide, N-(1-(bis(4-chlorophenyl)methyl)-3-azetidinyl)-n-(3,5-difluorophenyl)-
20. N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-n-(3,5-difluorophenyl)methanesulfonamide
Molecular Weight | 497.4 g/mol |
---|---|
Molecular Formula | C23H20Cl2F2N2O2S |
XLogP3 | 5.6 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 6 |
Exact Mass | 496.0590608 g/mol |
Monoisotopic Mass | 496.0590608 g/mol |
Topological Polar Surface Area | 49 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 686 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in alzheimer's disease, obesity, and schizophrenia and schizoaffective disorders.
AVE-1625 is a selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?